


## Malaysian Genomics Pivots to Biopharmaceuticals for Growth

*Group reports lower revenue for 2Q on switch to immunotherapy and cell therapies from vaccines*

**PETALING JAYA, 24 February 2023** – **Malaysian Genomics Resource Centre Berhad** (“Malaysian Genomics” or “the Group”), a leading genomics and biopharmaceutical specialist, today announced that the Group recorded a revenue of RM1.64 million for the second quarter ended 31 December 2022 (“2Q 2023”). This amount is down from RM7.63 million in 2Q 2022, as the Group moved its focus from vaccines to biopharmaceuticals.

For the quarter under review, the Group recorded a loss before tax (“LBT”) of RM1.27 million compared with a profit before tax (“PBT”) of RM1.01 million in 2Q 2022, mainly due to business expansion and production of fast-moving consumer goods (“FMCG”), which required additional human resource capital, research and development expenditure, and marketing.

For the first six months ended 31 December 2022 (“1H 2023”), the Group recorded a revenue of RM5.46 million, which is a RM11.48 million decrease from the RM16.94 million registered in 1H 2022. The Group reported a LBT of RM0.43 million for 1H 2023 compared to a PBT of RM1.25 million in the corresponding period in the previous financial year.



**Azri Azerai, Executive Director of Malaysian Genomics**, said, “Our Group remains committed to sustaining growth over the longer term by focusing on immunotherapy and cell therapies under the biopharmaceutical business we are expanding through our distribution network in the Middle East and Southeast Asia. We are also developing new FMCG products to offer to these new markets while seeking to expand into other markets. Our recent initiatives include a commercial collaboration on an innovative genetic test for reproductive health and the development of novel phytopharmaceuticals with potential therapeutic and commercial value.”

“The financial performance for the quarter under review was mainly affected by the need to spend in support of the pivot to biopharmaceuticals, which the Group is well positioned to take advantage of given our track record as a leading provider of genetic screening and genome analysis services,” he added.

###

### ABOUT MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

Malaysian Genomics Resource Centre Berhad (“MGRC” or “the Group”) is a leading genomics and biopharmaceutical company based in Southeast Asia. The Group was established in 2004 and listed on the Bursa Malaysia stock exchange in 2010. From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, MGRC has expanded into the biopharmaceutical sector with the manufacturing of cell therapies including immunotherapy for various types of cancer.

Utilising its high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, the Group is committed to improving access to the latest in precision and personalised healthcare solutions to improve the lives of patients.

---

For more information, visit [www.mgrc.com.my](http://www.mgrc.com.my).

---

**Issued By:** Swan Consultancy Sdn. Bhd. on behalf of Malaysian Genomics Resource Centre Berhad  
**Date:** 24 February 2023

**For more information, please contact:**

**Jazzmin Wan**

**Tel:** +60 17-289 4110

**Email:** [j.wan@swanconsultancy.biz](mailto:j.wan@swanconsultancy.biz)

**Amida Baharim**

**Tel:** +60 12-206 1209

**Email:** [a.baharim@swanconsultancy.biz](mailto:a.baharim@swanconsultancy.biz)

---